Switch to a Different Statin or Consider Ezetimibe Monotherapy
For a patient with diarrhea on pravastatin and itching on Repatha (evolocumab), the best approach is to try an alternative statin—preferably atorvastatin or rosuvastatin—since most patients with statin-related side effects can tolerate a different statin, and if that fails, use ezetimibe as monotherapy or in combination with the maximally tolerated statin dose.
Algorithmic Approach to This Patient
Step 1: Re-challenge with Alternative Statins
- Try atorvastatin or rosuvastatin first 1, 2
- Pravastatin-induced diarrhea is listed as a known adverse effect in the FDA label 3
- Studies show that 62-81% of patients with documented statin intolerance to one agent successfully tolerate a different statin 2
- At least 3 different statins should be attempted before declaring true statin intolerance 4, 2
- If high-intensity statin is not tolerated, consider pitavastatin (particularly if patient has metabolic syndrome or diabetes, as it has lower risk of new-onset diabetes) 5
Step 2: If Multiple Statins Fail
- Add ezetimibe 10 mg daily to the maximally tolerated statin dose 1
- Ezetimibe is generally well tolerated with proven cardiovascular outcomes benefit 1
- Note: Diarrhea is also listed as an adverse effect of ezetimibe (though less common than with statins), so monitor for this 1
- Provides additional 18% LDL-C reduction as monotherapy or 25% incremental reduction when combined with statins 1
Step 3: Consider Alternative PCSK9 Inhibitor
- Try alirocumab instead of evolocumab 1
- Since the patient experienced itching with evolocumab, switching to the alternative PCSK9 inhibitor (alirocumab) may be better tolerated
- Both have similar efficacy but individual tolerability can vary
- Injection site reactions are the most common adverse effects, but systemic symptoms like itching are less common 1, 6
Step 4: If PCSK9 Inhibitors Not Tolerated
- Consider bempedoic acid (if available) 5
- Can be used alone or combined with ezetimibe
- Particularly useful in patients with complete statin intolerance
- Does not cause muscle-related side effects
Step 5: Alternative Dosing Strategies
- Intermittent statin dosing (e.g., atorvastatin or rosuvastatin twice weekly) may be tolerated in some patients 2, 7
- Lower doses of high-intensity statins combined with ezetimibe often achieve better tolerability than high-dose statin monotherapy 4, 5
Key Clinical Pitfalls to Avoid
Don't abandon statins after one failure: The evidence strongly supports that most patients reporting statin intolerance can successfully tolerate an alternative statin 2, 8
Don't assume all side effects are drug-related: Many symptoms attributed to statins occur at similar rates in placebo groups. Consider a structured rechallenge protocol 4, 2
Don't use ezetimibe monotherapy as first-line: While ezetimibe can be used alone, combination therapy with even a low-dose statin provides superior cardiovascular risk reduction 4, 1
Don't ignore the cost-effectiveness hierarchy: Statins remain first-line; ezetimibe is second-line; PCSK9 inhibitors are reserved for high-risk patients not at goal despite maximally tolerated statin + ezetimibe 1, 9
Practical Implementation
Immediate next steps:
- Discontinue pravastatin
- Start atorvastatin 40 mg or rosuvastatin 20 mg daily
- If tolerated after 4-6 weeks and LDL-C not at goal, add ezetimibe 10 mg
- If new statin also causes intolerable side effects, try a third statin (consider pitavastatin or fluvastatin) 2, 7
- Only after documenting intolerance to at least 3 statins should you consider ezetimibe monotherapy or non-statin regimens 4, 2
For the PCSK9 inhibitor issue: If patient requires PCSK9 inhibition based on cardiovascular risk and LDL-C goals, trial alirocumab before abandoning this drug class entirely, as the itching may be specific to evolocumab 1.